Rigel Pharmaceuticals and Proteros extend research collaboration

23 April 2009

German company Proteros biostructures GmbH has announced an update on the research collaboration with Rigel Pharmaceuticals Inc. From the start of the collaboration allowing Rigel access to Gallery Structures, Proteros has consistently delivered high quality protein-ligand structural information which enables determination of the binding characteristics of compounds supplied by Rigel to facilitate subsequent compound optimisation.

Proteros has collaborated with Rigel since 2007 to solve the structures of multiple proteins, selected by Rigel from Proteros’ Gallery Structures collection, in combination with compounds and fragments supplied by Rigel to determine the binding mode of these compounds to the selected protein and enable the rapid and informed optimisation of the compounds and build up of the fragments.

By accessing Proteros’ Gallery Structures, a collection of seventy five industry relevant proteins pre-established at Proteros, rapid delivery of high quality protein-ligand structural information is assured.
Timely availability of such protein-ligand structure information has been an important element enabling Rigel’s scientists to accelerate entire drug discovery programmes. The financial terms of the collaboration which include research and success fees are not disclosed.

Bookmark this paget>

To top